- Home
- WOOF vs ESPR Comparison
WOOF vs ESPR Comparison
Compare WOOF & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOOF | ESPR |
|---|---|---|
| Founded | 1965 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.9M | 660.1M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | WOOF | ESPR |
|---|---|---|
| Price | $3.08 | $3.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 7 |
| Target Price | $3.92 | ★ $6.86 |
| AVG Volume (30 Days) | 3.3M | ★ 7.4M |
| Earning Date | 11-25-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,998,469,000.00 | $303,802,000.00 |
| Revenue This Year | N/A | $18.83 |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $2.28 | $0.69 |
| 52 Week High | $6.29 | $4.02 |
Technical Indicators
Market Signals| Indicator | WOOF | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 65.00 |
| Support Level | $3.03 | $2.66 |
| Resistance Level | $3.59 | $3.26 |
| Average True Range (ATR) | 0.17 | 0.24 |
| MACD | 0.05 | 0.10 |
| Stochastic Oscillator | 47.94 | 75.91 |
Price Performance
Historical ComparisonAbout WOOF Petco Health and Wellness Company Inc.
Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.